1. Fig. 1 Generation and characterization of MeV-based vaccine candidates for Lassa virus.
Generation and characterization of MeV-based vaccine candidates for Lassa virus. (A) Scheme of the MeV-based vaccines generated using the Schwarz strain. ATU, additional transcription unit. (B) Growth kinetics of vaccines in Vero NK cells. The results are presented as the means ± SEM of three independent experiments. (C) LASV NP, GPC, Z protein, and MeV F antigen expression in supernatants and cell extracts (cells) of infected Vero NK cells analyzed by Western blot. Actin was used to normalize the amount of loaded proteins. (D) Induction of type I IFN mRNA expression in primary human monocyte-derived dendritic cells (left graph) and macrophages (right graph) 1 day after infection by the MeV-based constructs. (E) Cell surface expression of coactivation molecules in primary human monocyte-derived dendritic cells (left graph) and macrophages (right graph) at day 2 after infection. Results (D and E) are presented as the means ± SEM of three or more independent experiments using different donors. (F) Infection of CHO-K1 or CHO-hCD46 cells by MOPEVACLAS or MeV-NP using an MOI of 1. LASV GPC (green) was detected by immunofluorescence 72 hours after infection. Nuclei are stained with DAPI (blue).
Mathieu Mateo et al., Sci Transl Med 2019;11:eaaw3163
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works